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Abstract
Background: In a cross-sectional analysis of cystic fibrosis (CF) patients with mild lung disease,
reduced surfactant activity was correlated to increased neutrophilic airway inflammation, but not
to lung function. So far, longitudinal measurements of surfactant function in CF patients are lacking
and it remains unclear how these alterations relate to the progression of airway inflammation as
well as decline in pulmonary function over time.
Methods:  As part of the BEAT trial, a longitudinal study to assess the course of airway
inflammation in CF, we studied lung function, surfactant function and endobronchial inflammation
using bronchoalveolar lavage fluid from 20 CF patients with normal pulmonary function (median
FEV1 94% of predicted) at three times over a three year period.
Results: There was a progressive loss of surfactant function, assessed as minimal surface tension.
The decline in surfactant function was negatively correlated to an increase in neutrophilic
inflammation and a decrease in lung function, assessed by FEV1, MEF75/25%VC, and MEF25%VC. The
concentrations of the surfactant specific proteins A, C and D did not change, whereas SP-B
increased during this time period.
Conclusion: Our findings suggest a link between loss of surfactant function driven by progressive
airway inflammation and loss of small airway function in CF patients with limited lung disease.
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Background
Cystic fibrosis (CF) is caused by mutations in the cystic
fibrosis transmembrane regulator (CFTR) gene and early
alterations are primarily found in the small airways [1].
Pulmonary surfactant is of critical importance for the
maintenance of airspace patency during the respiratory
cycle, especially at lower airway pressures at end-expira-
tion. These biophysical functions are predominantly
related to surfactant lipids [2,3], surfactant proteins (SP-)
B and -C, as well as SP-A which contributes to resistance
against inhibition of surfactant activity by products of
inflammation. Altered surfactant has been associated with
impaired lung function in young children with respiratory
infections [4,5]. Thus, derangements of any of these com-
ponents may affect the biophysical surfactant activity and
may contribute to early alterations of lung function in
patients with cystic fibrosis [6].
In a previous cross-sectional analysis of patients from the
BEAT (Broncho-alveolar Lavage for the Evaluation of Anti-
inflammatory Treatment) study, a long term study using
bronchoalveolar lavage (BAL) to assess the evolution of
airway inflammation in CF patients with normal lung
function, we have observed a reduction of surfactant activ-
ity reflecting impaired airway patency in the majority of
these CF patients [7]. The degree of surfactant dysfunction
was inversely correlated with neutrophilic endobronchial
inflammation, but no correlation was observed with flows
at low lung volumes (MEF25%VC or MEF25/75%VC).
Flows at low lung volumes have been used to assess these
early functional abnormalities, but due to inhomogene-
ous distribution of disease manifestation and a high inter-
individual variability, they have not been found to be par-
ticularly sensitive when used cross-sectionally [8,9]. Lon-
gitudinal assessment of lung function is more sensitive in
detecting deviations from personal best values [10,11].
Thus, sequential analyses appear to be more powerful to
detect pathological changes [12,13]. We hypothesized
that if surfactant function is relevant for small airway dis-
ease in CF patients, functional abnormalities in surfactant
should be related to deterioration in pulmonary function
assessed longitudinally. Some results of these studies have
been reported previously in the form of an abstract [14].
Materials and methods
Patients and samples
Patients with cystic fibrosis were recruited from the BEAT
study, a multi-center study using bronchoalveolar lavage
to evaluate the evolution of airway inflammation in CF
and its modulation by rhDNase treatment [15]. Inclusion
criteria were an established diagnosis of CF, the ability to
perform lung function tests, normal lung function defined
as a FEV1 > 80% predicted, and absence of acute respira-
tory tract infections prior to bronchoscopy for at least 6
weeks. Patients receiving anti-inflammatory treatment
(ibuprofen and systemic or inhaled corticosteroids), and
those with allergic bronchopulmonary aspergillosis were
excluded. The local ethic committees of all participating
centers approved the study; written informed consent by
both parents and/or patients was obtained in all cases.
BAL was performed prior to randomization, after 1.5 as
well as after 3 years in the same segment/subsegment over
time. For this study samples from all patients were consid-
ered in whom 3 BALs were performed and sufficient mate-
rial was available for analysis. More than 5 ml of BAL fluid
at all 3 time points was available in 37 of 105 subjects. The
measurement of surfactant proteins and functional assess-
ment in the capillary surfactometer required 2.5 ml, there-
fore 2.5 ml could be used for surface tensions
measurements in the bubble surfactometer. Since this
technique requires at least 40 µg of phospholipids, phos-
pholipid concentration had to be 16 µg/ml, which was the
case in 22 subjects. Two samples of two different subjects
were lost during processing; therefore 20 patients (13
females) with a median age of 10 years (range 5–16) were
left for the final analysis. 13 of the patients were dF508
homozygeous, 3 were dF508 compound heterozygeous,
in 2 patients other mutations were present, and in 2 the
mutations were unknown. Four of the 20 patients were
positive for P. aeruginosa. FVC was 91% pred. (70–126),
FEV1 94% pred. (76–118), MEF25%VC  69% pred. (27–
155)). The status of infection, i.e. the type of bacteria
recovered from the airway specimens and serum values
for C-reactive protein, total IgG and neutrophils were the
same at all 3 time points assessed. The subpopulation did
not differ from the total study population in both pulmo-
nary function and baseline BAL parameters. 9 of 20
patients were randomized to rhDNase once daily. Because
of the small number of patients in these subgroups, a sub-
analysis related to rhDNase treatment was not performed
in this study. For comparison to the levels in normal chil-
dren, the mean and range of the biophysical and cellular
measures in healthy children are indicated in the figures
where appropriate. These and additional data obtained
with the same methods can be found in a previous publi-
cation [7].
Bronchoalveolar lavage (BAL), sample preparation and 
biochemical and biophysical measurements
BAL was performed as described with 3 × 1 ml/kg body
weight normal saline warmed to body temperature
[15,16]. The first aliquot of the recovered BAL fluid was
treated separately; all other samples were pooled for anal-
ysis. The total cell count was measured in a hemocytome-
ter, the differential cell count was assessed from cytoprep
slides. Aliquots of the cell free BAL supernatant of the
pooled BAL sample were used for the analysis of total pro-
tein, and the surfactant proteins by ELISA (SP-A, SP-D
[17] and SP-B, SP-C [18,19]). Pulmonary surfactant mayRespiratory Research 2005, 6:133 http://respiratory-research.com/content/6/1/133
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Quality control assurance by the assessment the function of a bovine surfactant (minimal surface tension, closed squares; sur- face tension after adsorption, open squares) and of water (minimal surface tension, closed circles; surface tension after adsorp- tion, open squares) in the pulsating bubble surfactometer (upper panel) and the capillary surfactometer (lower panel) (bovine  surfactant, closed squares, water, open squares) over a period of more than two years Figure 1
Quality control assurance by the assessment the function of a bovine surfactant (minimal surface tension, closed squares; sur-
face tension after adsorption, open squares) and of water (minimal surface tension, closed circles; surface tension after adsorp-
tion, open squares) in the pulsating bubble surfactometer (upper panel) and the capillary surfactometer (lower panel) (bovine 
surfactant, closed squares, water, open squares) over a period of more than two years.Respiratory Research 2005, 6:133 http://respiratory-research.com/content/6/1/133
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be differentiated into a very surface active fraction, i.e. the
large surfactant aggregates (LA) and a less active fraction
containing smaller surfactant particles (small aggregates,
SA), which may also inhibit surfactant function. 5 ml aliq-
uots of the BAL fluid were centrifuged at 40,000 × g for 30
min to generate a surfactant pellet, containing the LA and
the supernatant, containing the SA [19]. The phospholi-
pid content was determined by phosphorus assay of a
lipid extract of the surfactant pellet [19]. After resuspen-
sion of the surfactant pellet (NaCl 140 mM, HEPES 10
mM, EDTA 0.5 mM, CaCl2 3.5 mM, pH 6.9) the surface
activity was assessed in a pulsating bubble surfactometer
at a final phospholipid concentration of 1 mg/ml [19]. In
addition, the biophysical activity was assessed in a capil-
lary surfactometer [20]. Briefly, glass capillaries (0.255
mm internal diameter at its most narrow part) were filled
with 0.5 µl of the above described surfactant suspension
and assessed for the capability at 37°C to keep the capil-
lary open over a time period of 120 seconds. Water (0% of
the time open) and a purified bovine surfactant (96.7% of
the time open) served as a control [20].
Reliability and precision of the measurements of surface
activity was assured by the regular assessment of a well
functioning bovine surfactant, water and methanol each
working day (Fig. 1). Appropriate and stable readings
Surface activity of a surfactant fraction obtained from bronchoalveolar lavages in 20 patients with cystic fibrosis assessed in a  pulsating bubble surfactometer (upper left panel), i.e. expressed as surface tension at minimum bubble radius (squares) and sur- face tension at adsorption (triangles), assessed in a capillary surfactometer (lower left panel), i.e. expressed as the percentage  of time open of a small capillary of total time Figure 2
Surface activity of a surfactant fraction obtained from bronchoalveolar lavages in 20 patients with cystic fibrosis assessed in a 
pulsating bubble surfactometer (upper left panel), i.e. expressed as surface tension at minimum bubble radius (squares) and sur-
face tension at adsorption (triangles), assessed in a capillary surfactometer (lower left panel), i.e. expressed as the percentage 
of time open of a small capillary of total time. The percentage of neutrophils (upper right panel) and the absolute number of 
neutrophils (lower right panel) as markers of inflammation in their BAL fluids are also indicated. Data are given as mean and 
standard error of the mean. Differences between the different time points were assessed by nonparametric Friedman 
ANOVA, followed by Dunn's post hoc multiple comparison test. The asterisks indicates a significantly different value, com-
pared to the first data point (* P < 0.05, ** P < 0.01). The open symbols represent values in normal subjects assessed with the 
same methodolgy [7,29].Respiratory Research 2005, 6:133 http://respiratory-research.com/content/6/1/133
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were obtained over a period of more than 2 years for the
pulsating bubble surfactometer and also the capillary sur-
factometer, except for two days with high readings in the
capillary surfactometer towards the end of the study (Fig.
1, lower panel). These high readings were related to prob-
lems with the diameter of the capillaries and new batches,
which gave the expected lower values, were used.
Statistical analysis
The nonparametric ANOVA, i.e. Friedman test was used
for comparison of repeated measured values over the
study period at the 3 time points, followed by the Dunn's
post-hoc test to detect differences between each time
points. Correlations were calculated with the Spearman
rank test. Non-paired comparisons were made with the
nonparametric Mann-Whitney test. The results are given
as medians and ranges or as individual values (mean of 2
to 4 determinations). A p level of <0.05 was considered
statistically significant. Statistical analysis was done with
Prism 4.
Results
Minimum surface tension increased, reflecting deteriorat-
ing function, over the 3-year period (Fig. 2, left upper
panel). This was paralleled by an increase in the relative
and total number of neutrophils (Fig. 2, right panels). The
increase of minimum surface tension over the 3 years was
directly proportional to an increase in neutrophils (Fig. 3,
upper panel). The total amount of phospholipids in BAL
fluid was higher in the initial BAL than in the two follow-
ing studies (Tab. 1). This finding is not responsible for the
observed loss of surfactant function, which was assessed at
a fixed phospholipid concentration. Surfactant function
assessed in the capillary surfactometer, which was already
severely reduced at baseline compared to values in healthy
children, improved slightly after 1.5 years, but did not
change significantly over the 3 year period (Fig. 2).
Lung function assessed as FEV1 significantly deteriorated
over time (Fig. 4, upper panel). This trend was even more
pronounced for lung function parameters representing
predominantly the small airways (MEF75/25 and MEF25)
(Fig. 4, lower panels). The changes of all three measures of
airway obstruction used here, were negatively correlated
to an increase of minimal surface tension (FEV1 r = -0.560,
P = 0.009, MEF25%VC r = -0.536, P = 0.015 and MEF75/25%VC
see Fig. 3, lower panel).
The concentration of the surfactant specific proteins SP-A,
C and D, as well as the total protein content of BAL fluid
did not change significantly, whereas SP-B was higher
after 1.5 and 3 years than at the beginning (Table 1).
In the absence of reduced concentrations of the surfactant
proteins, proteolytic attack resulting in inactivation and
the presence of fragments of the proteins, may also be
responsible for dysfunction of surfactant [21,22]. No such
fragments were found by Western blotting for SP-B and
SP-C in 21 CF patients over the range of neutrophilic
inflammation, present in this cohort (Tafel, Latzin and
Griese, unpublished observations). BALs from 15 CF
patients from this cohort were screened for proteolytic
fragments of SP-A. In 3 subjects weak bands were found;
one band at 23 kD, one at 18 kD and in another subject
one at 16 kD. These bands contributed to less than 1% of
the total SP-A present on each of the blots (Wassilewa and
Griese, unpublished data).
The surface active fraction of pulmonary surfactant, i.e.
the large surfactant aggregates (LA) can be separated from
the less active small aggregates, i.e. SA, which may also
inhibit surfactant function. We next investigated the con-
tribution of the SA fraction to overall surfactant function.
Correlation of the change in surfactant activity, assessed as  minimal surface tension, to the change of the fraction of pol- ymorphonuclear leukocytes in BAL (upper panel) and to the  change of small airway function, assessed as MEF75/25 (lower  panel) Figure 3
Correlation of the change in surfactant activity, assessed as 
minimal surface tension, to the change of the fraction of pol-
ymorphonuclear leukocytes in BAL (upper panel) and to the 
change of small airway function, assessed as MEF75/25 (lower 
panel). Changes were calculated as the difference between 
the last visit at 3 years and the first visit at start of the study. 
Spearman rank correlations and linear regression line are 
indicated.Respiratory Research 2005, 6:133 http://respiratory-research.com/content/6/1/133
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SA added to LA at the original ratio present in bronchoal-
veolar lavage, significantly reduced surfactant function
both, in the pulsating and in the capillary surfactometer
(Fig. 5, left panels). Interestingly, this effect was not
related to the protein content of SA (Fig. 5, right panels).
To clarify this issue further, we asked the question, if the
SA protein which has a similar protein composition as
serum [21], differed from serum in its potency to inhibit
surfactant, i.e. from the presence of components that have
an intrinsically higher capacity to inhibit surfactant func-
tion. No such differences were found at two representative
concentrations of SA investigated (Tab. 2).
Discussion
This is the first study to assess surfactant function, lung
function and airway inflammation longitudinally in CF
patients. The results demonstrate loss of surfactant func-
tion over time parallel to an increase in neutrophilic
inflammation and a decrease in small airway function.
These data support the hypothesis that inflammation
leads to disturbances of the local airspace environment,
including properties of the surfactant system resulting in a
loss of patency of small airways.
The mechanism(s) responsible for this loss of surfactant
function remain to be resolved. An altered phospholipid
composition could contribute to reduced surface activity,
but this appears rather unlikely, as no significant devia-
tions have previously been found in a group of younger
CF patients [4,23]. Similarly, no age dependency of the
four surfactant proteins, total phospholipid and total pro-
tein, was observed in the whole cohort of CF patients from
the BEAT study spanning an age range from 5 to 31 years
(n = 75) [7]. Here we did not find reductions in the con-
centrations of the four surfactant proteins over time, sug-
gesting that the loss of surface activity cannot be easily
explained by a single factor like an altered expression of
one of the surfactant proteins. Alterations of the integrity
and function of the surfactant proteins without a change
in their concentration, such as by proteolytic degradation,
were largely excluded as we found no such fragments for
SP-B and SP-C (Tafel, Latzin and Griese, unpublished
data). For SP-A in 3 out of 15 investigated patients very
small amounts of SP-A degradation products (<1% of
total SP-A present) were detected by Western blotting,
which was unlikely to be of functional relevance (Was-
silewa and Griese, unpublished data). In addition to pro-
teolytic damage, oxidative modification of the proteins
may occur and contribute to surfactant protein dysfunc-
tion, however this was not assessed systematically in this
cohort [21,22,24,25]. Little pronounced, but continu-
ously ongoing inflammatory processes may gradually
evoke changes in the function of the surface active fraction
of surfactant, which may be responsible for the observed
loss of biophysical surfactant activity. The principal sur-
face active fraction of pulmonary surfactant recovered
from the airspaces is represented the large surfactant
aggregates (LA). Early changes in the LA surfactant micro-
texture like an increased admixture of inactivating compo-
nents from the SA fraction with enhanced local inflamma-
tion could be involved [26]. This explanation does not
necessitate changes in the intrinsic inhibitory potency of
the SA proteins and is in accordance with our results that
SA fractions did not differ in their surfactant function and
had a similar inhibitory potency as serum.
In our previous cross-sectional study of the same cohort of
CF patients, we observed only a marginally decreased sur-
factant function assessed in the pulsating bubble surfac-
tometer [7]. When those samples were analysed in the
more sensitive capillary surfactometer, which simulates a
small airway, the functional capacity of the surfactant was
more extensively impaired with a mean capillary open-
ness below 20% [7]. Open small airways are critical for
the reduction of overinflation, the deposition of anti-
inflammatory and anti-microbial treatments in those
areas of the lungs where the initial neutrophilic inflam-
mation begins to destroy the lung's integrity of patients
with CF. The lack of change over time observed in this
study with the capillary surfactometer may be caused by
Table 1: Surfactant proteins (SP-) A, B, C and D, total proteins and phospholipids in three consecutive bronchoalveolar lavages (BAL) 
in patients with cystic fibrosis over a 3 year period
1. BAL at start of the study 2. BAL after 1.5 years 3. BAL after 3 years
SP-A (ng/ml) 5312.0 (2409.0 – 13218.0) 5580.0 (1334.0 – 13048.0) 3782.0 (128.6 – 13624.0)
SP-B (ng/ml) 397.5 (247.2 – 1219.0) 897.5 (472.5 – 1252.0)† 847.0 (375.5 – 1602.0) **
SP-C (ng/ml) 635.0 (37.0 – 1557.0) 638.7 (391.5 – 2012.0) 581.2 (15.5 – 1489.0)
SP-D (ng/ml) 7.41 (1.17 – 22.06) 5.41 (1.48 – 43.46) 6.25 (0.00 – 48.21)
Protein (µg/ml) 104.70 (52.60 – 382.40) 97.88 (46.60 – 193.40) 94.20 (38.44 – 258.80)
Phospholipids (µg/ml) 50.37 (19.45 – 102.50) 33.56 (20.75 – 429.40) 32.64 (14.84 – 70.00) **
Comparisons were made by Friedman test followed by Dunn's post hoc test. Differences between the beginning and the end of the study are 
indicated by **, differences between the first and second BAL are indicated by †. Level of significance († P < 0.05, ** P < 0.01). Data are median 
(range) of 20 patients.Respiratory Research 2005, 6:133 http://respiratory-research.com/content/6/1/133
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this marked reduction observed already at baseline ren-
dering this methodology too sensitive to detect further
impairments in surfactant function over time.
Of interest is a lack of correlation between minimal sur-
face tension assessed in the pulsating bubble surfactome-
ter and the % open assessed in the capillary surfacometer
(r = -0.060; P = 0.768), when the same samples were
assessed. Also, the changes of these variables over time did
not correlate with each other. Identical results were
obtained previously in the larger BEAT cohort (n = 75)
investigated similarly for these two variables (r = -0.140; P
= 0.095) [7]. Together these data demonstrate that the two
techniques have different sensitivities and may also meas-
ure two distinct aspects of surfactant activity of airway
specimens.
Using the pulsating bubble surfactometer and assessing
minimal surface tension, loss of surfactant activity was
detected with time. The concordance of the increase of
minimal surface tension, loss of lung function, including
small airways function and their inverse correlation sup-
port the concept that the surfactant function may be rele-
vant for the stability of small airways [20,27]. Thus
treatment strategies directed to keep the small airways pat-
ent, i.e. physiotherapeutic interventions maintaining a
positive expiratory pressure or inhalation of exogenous
surfactant [28] may be relevant for the treatment of early
CF lung disease.
There are some important limitations of this study that
need to be taken into account when interpreting the data.
First, the number of patients reported in this cohort is rel-
atively small and consists of a subgroup of the total study
cohort [16]. However, we found no significant differences
in CFTR genotype, sex, baseline lung function, bacterial
colonisation and BAL neutrophils at baseline between the
cohort reported here and the total BEAT study population.
Lung function over time in 20 subjects with CF Figure 4
Lung function over time in 20 subjects with CF. FEV1, MEF72/25%VC and MEF25%VC were significantly lower 3 years after start of 
the study (Friedman ANOVA, followed by Dunn' post hoc multiple comparison test, * p < 0.05, *** p < 0.001). FVC did not 
change.Respiratory Research 2005, 6:133 http://respiratory-research.com/content/6/1/133
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In the original report of the BEAT study results, we have
observed an inhibiting effect of rhDNase on airway
inflammation over time and this may also influence the
data reported here. When we compared the changes in a
subgroup analysis, we did not observe any differences in
change of surfactant function over time between the 2
groups, but this finding has to be interpreted with cau-
tion, because the number of patients included is too small
to detect effects of rhDNase. Similarly, the other variables
assessed here, i.e. surfactant function and airspace inflam-
mation were not different between the subgroups. Finally,
bacterial infection changes over time and this may impact
upon both inflammation and surfactant function. Again,
subgroup analysis is problematic because of small num-
bers. The change in surfactant function showed no rela-
tionship to changes in bacterial colonisation, which may
be related to the fact that most patients were already
infected with CF pathogens. The effect of bacterial infec-
tion should therefore ideally be studied in a population
which does not have airway infection initially.
Our data are in agreement with previous cross-sectional
studies in children with CF including patients with
impaired lung function, where minimal surface tension
Surfactant activity assessed in the pulsating bubble surfactometer (upper panels) and the capillary surfactometer (lower panels) Figure 5
Surfactant activity assessed in the pulsating bubble surfactometer (upper panels) and the capillary surfactometer (lower panels). 
The large aggregate (LA) surfactant fraction was recombined with the appropriate small aggregates (SA) of surfactant, demon-
strating significant inhibitory activity (left side panels). This inhibitory activity of SA was not dependent on its amount, i.e. was 
not the sole determinate of surface activity (right side panels). Comparisons by Mann-Whitney test and correlations by Spear-
man rank test.Respiratory Research 2005, 6:133 http://respiratory-research.com/content/6/1/133
Page 9 of 10
(page number not for citation purposes)
was reduced, whereas the concentrations of total phos-
pholipids and of dipalmitoyl phosphatidylcholine were
within the normal range [4,23]. Similar observations were
made in older children and young adults [19], suggesting
that there may be an early, but secondary, derangement of
the biophysical surfactant properties in CF. With this lon-
gitudinal study of CF patients we hoped to eliminate a
substantial fraction of the variability by investigating the
changes within individuals overtime. Despite a large
cohort of patients to start with [16], eventually only 20
complete triplets of sufficient BAL fluid were available for
all the biophysical measurements. Nevertheless, we found
a clear increase in minimal surface tension over the time
period investigated and also correlations between these
changes, the changes in lung function and an increase in
neutrophils.
In summary, pulmonary surfactant function, lung func-
tion and airway inflammation were assessed sequentially
over a 3-year period in CF patients with initial lung func-
tion within the normal range. An increase in neutrophil
inflammation over time was associated with a decrease in
small airway function and a loss of surfactant activity.
These findings highlight the importance of early changes
in small airway biology and strongly suggest that specific
therapeutic interventions targeting this region of the lung
are warranted.
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